ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics

Cytometry Part A

Volumn 75, Issue 11, 2009, Pages 924-933

  Smith, Paul J ^a   Furon, Emeline ^a   Wiltshire, Marie ^a   Campbell, Lee ^a   Feeney, Graham P ^a,b   Snyder, Ronald D ^c   Errington, Rachel J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ABCG2; Drug resistance; Hoechst 33342; Lung cancer; Side population; Topotecan

Indexed keywords

ALDEHYDE DEHYDROGENASE; BREAST CANCER RESISTANCE PROTEIN; CELL DNA; GLUTATHIONE TRANSFERASE; HOE 33342; NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) TRANSHYDROGENASE; POLO LIKE KINASE 2; PUTRESCINE; SPERMIDINE; SPERMINE; TALLIMUSTINE; TOPOTECAN;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL ISOLATION; CELL POPULATION; CELL PROTECTION; CELL SURVIVAL; CELL TRANSPORT; CELLULAR STRESS RESPONSE; CROSS LINKING; CYTOTOXICITY; EXPERIMENTAL MODEL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; L CELL; LUNG ADENOCARCINOMA; MICROARRAY ANALYSIS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSPORT KINETICS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL SEPARATION; CROSS-LINKING REAGENTS; DISTAMYCINS; ENZYME INHIBITORS; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; LIGANDS; MICE; NITROGEN MUSTARD COMPOUNDS; POLYAMINES; TOPOTECAN;

EID: 71049181517     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20800     Document Type: Article

References (57)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
2. Hart LS, El-Deiry WS. Invincible, but not invisible: Imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol 2008;26:2901-2910.
3. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
4. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH. Identification of cells initiating human melanomas. Nature 2008;451: 345-349.
5. Hughes OR, Stewart R, Dimmick I, Jones EA. A critical appraisal of factors affecting the accuracy of results obtained when using flow cytometry in stem cell investigations: Where do you put your gates? Cytometry Part A 2009;75A:803-810.
6. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-7358. (Pubitemid 37487163)
7. Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD. Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol 2003;64:1452-1462. (Pubitemid 37532235)
8. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000;60:47-50. (Pubitemid 30058728)
9. Ross DD, Doyle LA. Mining our ABCs: Pharmacogenomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell 2004;6:105-107.
10. Goodell MA, McKinney-Freeman S, Camargo FD. Isolation and characterization of side population cells. Methods Mol Biol 2005;290:343-352.
11. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK. A distinct "side population" of cells in human tumor cells: Implications for tumor biology and therapy. Cell Cycle 2005;4:203-205.
12. Srivastava VK, Nalbantoglu J. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. Cytometry Part A 2008;73A:940-948.
13. Benchaouir R, Picot J, Greppo N, Rameau P, Stockholm D, Garcia L, Paldi A, Laplace-Builhe C. Combination of quantification and observation methods for study of "Side Population" cells in their "in vitro" microenvironment. Cytometry Part A 2007;71A:251-257.
14. Smith PJ, Nakeff A, Watson JV. Flow-cytometric detection of changes in the fluorescence emission spectrum of a vital DNA-specific dye in human tumour cells. Exp Cell Res 1985;159:37-46. (Pubitemid 16247552)
15. Durand RE, Olive PL. Cytotoxicity, Mutagenicity and DNA damage by Hoechst 33342. J Histochem Cytochem 1982;30:111-116.
16. Chen AY, Yu C, Gatto B, Liu LF. DNA minor groove-binding ligands: A different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci USA 1993;90:8131-8135. (Pubitemid 23260869)
17. Sunavala-Dossabhoy G, Van Dyke MW. Combinatorial identification of a novel consensus sequence for the covalent DNA-binding polyamide tallimustine. Biochemistry 2005;44:2510-2522. (Pubitemid 40279554)
18. Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, Titley I, Schinkel AH, Dale TC. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 2005;23:1059-1065. (Pubitemid 41377721)
19. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007;67: 4827-4833. (Pubitemid 46910191)
20. Sung JM, Cho HJ, Yi H, Lee CH, Kim HS, Kim DK, Abd El-Aty AM, Kim JS, Landowski CP, Hediger MA, Shin HC. Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 2008;371:163-167.
21. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005;65:6207-6219. (Pubitemid 40994406)
22. Polgar O, Robey RW, Bates SE. ABCG2: Structure, function and role in drug response. Expert Opin Drug Metab Toxicol 2008;4:1-15. (Pubitemid 351234097)
23. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: Determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007;26:39-57. (Pubitemid 46452182)
24. Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH, Schinkel AH. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann N Y Acad Sci 2000;922: 188-194.
25. Koster DA, Palle K, Bot ES, Bjornsti MA, Dekker NH. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 2007;448:213-217. (Pubitemid 47067371)
26. Pommier Y. Camptothecins and topoisomerase I: A foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: Importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anticancer Agents 2004;4:429-434.
27. Cheung SY, Evans ND, Chappell MJ, Godfrey KR, Smith PJ, Errington RJ. Exploration of the intercellular heterogeneity of topotecan uptake into human breast cancer cells through compartmental modelling. Math Biosci 2008;213:119-134.
28. Debenham PG, Webb MB. Dominant mutation in mouse cells associated with resistance to Hoechst 33258 dye, but sensitivity to ultraviolet light and DNA base-damaging compounds. Somat Cell Mol Genet 1987;13:21-32.
29. Smith PJ, Lacy M, Debenham PG, Watson JV. A mammalian cell mutant with enhanced capacity to dissociate a bis-benzimidazole dye-DNA complex. Carcinogenesis 1988;9:485-490. (Pubitemid 18067970)
30. Gryczynski I, Gryczynski Z, Lakowicz JR, Yang D, Burke TG. Fluorescence spectral properties of the anticancer drug topotecan by steady-state and frequency domain fluorometry with one-photon and multi-photon excitation. Photochem Photobiol 1999;69:421-428. (Pubitemid 129555303)
31. Khan QA, Pilch DS. Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site. J Mol Biol 2007;365:561-569.
32. Kit S, Dubbs DR, Piekarski LJ, Hsu TC. Deletion of thymidine kinase activity from L cells resistant to bromodeoxyuridine. Exp Cell Res 1963;31:297-312.
33. Smith PJ, Bell SM, Dee A, Sykes H. Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: Ligand-induced DNA-protein crosslinking and responses to topoisomerase poisons. Carcinogenesis 1990;11:659-665. (Pubitemid 20137418)
34. Smith PJ, Debenham PG, Watson JV. A role of DNA topoisomerases in the active dissociation of DNA minor groove-ligand complexes. A flow cytometric study of inhibitor effects. Mutat Res 1989;217:163-172.
35. Rowe TC, Chen GL, Hsiang YH, Liu LF. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 1986;46(4 Part 2):2021-2026.
36. Feeney GP, Errington RJ, Wiltshire M, Marquez N, Chappell SC, Smith PJ. Tracking the cell cycle origins for escape from topotecan action by breast cancer cells. Br J Cancer 2003;88:1310-1317. (Pubitemid 36606351)
37. Bowlin TL, McKown BJ, Sunkara PS. Ornithine decarboxylase induction and polyamine biosynthesis are required for the growth of interleukin-2- and interleukin-3-dependent cell lines. Cell Immunol 1986;98:341-350.
38. Seiler N, Bolkenius FN, Knodgen B, Haegele K. The determination of N1-acetylspermine in mouse liver. Biochim Biophys Acta 1981;676:1-7.
39. Smith PJ, Blunt N, Wiltshire M, Hoy T, Teesdale-Spittle P, Craven MR, Watson JV, Amos WB, Errington RJ, Patterson LH. Characteristics of a novel deep red/infrared fluorescent cell-permeant DNA probe, DRAQ5, in intact human cells analyzed by flow cytometry, confocal and multiphoton microscopy. Cytometry 2000;40:280-291. (Pubitemid 30643187)
40. Watson JV, Nakeff A, Chambers SH, Smith PJ. Flow cytometric fluorescence emission spectrum analysis of Hoechst-33342-stained DNA in chicken thymocytes. Cytometry 1985;6:310-315. (Pubitemid 15060314)
41. Errington RJ, Ameer-Beg SM, Vojnovic B, Patterson LH, Zloh M, Smith PJ. Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cells. Adv Drug Deliv Rev 2005;57:153-167. (Pubitemid 39424070)
42. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159. (Pubitemid 17064313)
43. Davis SK, Bardeen CJ. Cross-linking of histone proteins to DNA by UV illumination of chromatin stained with Hoechst 33342. Photochem Photobiol 2003;77:675-679.
44. Snyder RD, Vogelpohl SJ, Baldwin BL, Deaton ED, Baden E, Carter JH. Apparent inhibition of apoptosis by polyamines and aminothiols in DNA fragmentation assays is artifactual. Cell Death Differ 1996;3:323-330. (Pubitemid 26317043)
45. Fontana M, Lestingi M, Mondello C, Braghetti A, Montecucco A, Ciarrocchi G. DNA binding properties of FCE24517, an electrophilic distamycin analogue. Anticancer Drug Des 1992;7:131-141.
46. Evans ND, Errington RJ, Shelley M, Feeney GP, Chapman MJ, Godfrey KR, Smith PJ, Chappell MJ. A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan. Math Biosci 2004;189:185-217. (Pubitemid 38496522)
47. Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996;87:1097-1103. (Pubitemid 26043537)
48. Bracht K, Liebeke M, Ritter CA, Grunert R, Bednarski PJ. Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: Comparison with the national cancer institute data. Anticancer Drugs 2007;18:389-404. (Pubitemid 46712402)
49. Matthew EM, Yen TJ, Dicker DT, Dorsey JF, Yang W, Navaraj A, El-Deiry WS. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle 2007;6:2571-2578. (Pubitemid 350058677)
50. Freeman H, Shimomura K, Cox RD, Ashcroft FM. Nicotinamide nucleotide transhydrogenase: A link between insulin secretion, glucose metabolism and oxidative stress. Biochem Soc Trans 2006;34(Part 5):806-810. (Pubitemid 44796426)
51. Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact 2000;129:1-19. (Pubitemid 32061051)
52. Loo TW, Bartlett MC, Clarke DM. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol Pharmacol 2004;1:426-433.
53. PajicM, Iyer JK, Kersbergen A, van der Burg E, Nygren AO, Jonkers J, Borst P, Rottenberg S. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res 2009;69:6396-6404.
54. Fox ME, Smith PJ. Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells. Cancer Chemother Pharmacol 1995;35:403-410.
55. Takagi K, Dexheimer TS, Redon C, Sordet O, Agama K, Lavielle G, Pierre A, Bates SE, Pommier Y. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. Mol Cancer Ther 2007;6(12 Part 1):3229-3238.
56. Lagas JS, Sparidans RW, van Waterschoot RA, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin. Antimicrob Agents Chemother 2008;52:1034-1039. (Pubitemid 351358385)
57. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-659.